Koers Herantis Pharma Oyj Nasdaq Helsinki
Aandelen
FI4000087861
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 1,3 mln. 1,4 mln. | Omzet 2025 * | - | Marktkapitalisatie | 29,23 mln. 31,48 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -3 mln. -3,23 mln. | Nettowinst (verlies) 2025 * | -4 mln. -4,31 mln. | EV/omzet 2024 * | 19,3 x |
Nettoliquiditeiten 2024 * | 4,2 mln. 4,52 mln. | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-
| K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 69,93% |
Recentste transcriptie over Herantis Pharma Oyj
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | - | 01-01-08 | |
Antti Vuolanto
CEO | Chief Executive Officer | - | 12-02-18 |
Tone Kvåle
DFI | Director of Finance/CFO | 55 | 26-10-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 53 | 01-01-14 | |
Director/Board Member | 53 | 11-03-20 | |
Chairman | 64 | 01-01-12 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |